memantine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   73 Trials   73 Trials   1509 News 


«12...25262728293031323334353637»
  • ||||||||||  memantine / generics
    Journal:  NMDA Antagonists for Treatment-Resistant Depression. (Pubmed Central) -  Jul 24, 2019   
    ...Of the other investigational agents, CERC-301 and rapastinel remain in clinical development...Research is still needed to determine the appropriate dose, schedule, and ways to mitigate against unwanted side effects of NMDA receptor blockade. These hurdles need to be overcome before ketamine and similar agents can be prescribed routinely to patients.
  • ||||||||||  memantine / generics
    Journal:  Toward higher extraction and enrichment factors via a double-reservoirs microfluidic device as a microextractive platform. (Pubmed Central) -  Jul 18, 2019   
    ...As extractive phases, two identical sheets of electrospun polyamide/polypyrrole/titania nanofibers were synthesized using core-shell electrospinning technique and utilized for determination of memantine in plasma samples...In addition, the interday and intraday precisions were lower than 6.7% (n = 3). The linearity was in the range of 0.14-75.00 ng mL , while recoveries were between 94.1 and 98.4% with the regression coefficient of 0.9987.
  • ||||||||||  ketamine / generics, sirolimus / generics, memantine / generics
    Biomarker, Journal:  Investigation of the underling mechanism of ketamine for antidepressant effects in treatment-refractory affective disorders via molecular profile analysis. (Pubmed Central) -  Jul 10, 2019   
    ...Differentially expressed genes (DEGs) were identified in hippocampus or striatum samples treated with ketamine, phencyclidyne or memantine compared with a saline or normal group at 1, 2, 4 and 8 h. The overlapping DEGs were the DEGs in both hippocampus and striatum samples...Both Sgk1 and Klf2 were enriched in the 'forkhead box O (FoxO) signaling pathway', and Sgk1 was additionally enriched in the 'mechanistic target of rapamycin kinase (mTOR) signaling pathway'...The four genes, Plin4, Sgk1, Klf2 and Dcaf12l1, were differentially expressed in all of the groups that treated with the three drugs and their expression levels were verified in in vivo experiments. The FoxO and mTOR signaling pathways may be involved in the underlying mechanism of the antidepressant effects of ketamine, and Plin4, Sgk1, Klf2 and Dcaf12l1 may be potential biomarkers for depression in N-methyl-D-aspartic acid receptor antagonist treatment.
  • ||||||||||  memantine / generics
    Journal:  Can an FDA-Approved Alzheimer's Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus? (Pubmed Central) -  Jul 1, 2019   
    Thus, blockage of the NMDAR channel activity with FDA-approved memantine or other antagonists may reduce neurological complications associated with Zika virus infection. Repurposing a preapproved drug and targeting the host represent intriguing strategies and yet require more analysis prior to moving into clinical trials.
  • ||||||||||  memantine / generics
    Retrospective data, Journal, Combination therapy:  Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. (Pubmed Central) -  Jun 28, 2019   
    MEM+SRI was superior to placebo+SRI with regard to response rate [primary outcome, n = 97; risk ratio = 0.22; 95% confidence intervals (CI) = 0.12-0.42; p < 0.00001; I2 = 0%; number needed to treat = 2], the Yale- Brown Obsessive- Compulsive Scale total [standardized mean difference (SMD) = - 4.56; 95% CI = - 8.50, - 0.62; p = 0.02], obsession subscale (SMD = - 4.39; 95% CI = - 5.94, - 2.85; p < 0.00001), and compulsion subscale score (SMD = - 4.60; 95% CI = - 7.64, - 1.55; p = 0.003). No significant differences in any safety outcome were found between the groups.
  • ||||||||||  Journal:  Benzofuran and indole: A promising scaffold for drug development in Alzheimer's disease. (Pubmed Central) -  Jun 26, 2019   
    Looking at the wide pharmaceutical applications of heterocyclic compounds and particularly those containing benzofuran and indole ring system; these molecular frameworks draw special attention of the medicinal chemists for further evaluation in numerous diseases. This article focuses on the history and recent advances of benzofuran and indole based compounds as inhibitors of butyrylcholinesterase (BuChE), acetylcholinesterase (AChE), γ-secretase, β-secretase, tau misfolding, and β-amyloid (Aβ) aggregation.
  • ||||||||||  Review, Journal:  Treatment Options for Agitation in Dementia. (Pubmed Central) -  Jun 25, 2019   
    Treatment with low doses of atypical antipsychotics such as risperidone or quetiapine can be effective after appropriate consideration of and disclosure of potential adverse effects...Considering the heterogeneity of patients and their comorbidities as well as the specific nature of their "agitation", there is no "one-size fits all" approach to agitation in AD. However, many options exist that can be prudently pursued for this common problem in this delicate population.
  • ||||||||||  memantine / generics
    Clinical, Journal:  Kihito, a Traditional Japanese Kampo Medicine, Improves Cognitive Function in Alzheimer's Disease Patients. (Pubmed Central) -  Jun 21, 2019   
    ...The exclusion criteria were as follows: (1) change in ChEI dosage, (2) memantine usage, and (3) MMSE score < 15...RBANS-J test scores had a slight improvement during the kihito intake period compared with the ChEI alone treatment period, but no significant changes were observed. Kihito improves cognitive function in AD patients.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Jun 17, 2019   
    P3,  N=721, Active, not recruiting, 
    The study findings highlight the complexity surrounding optimising dementia pharmacotherapy and antidementia medication withdrawal, highlighting the need for treatment to be person-centred and highly individualised. Trial primary completion date: Apr 2019 --> Dec 2019
  • ||||||||||  memantine / generics, carbamazepine / generics, amantadine / generics
    Clinical, Review, Journal:  A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. (Pubmed Central) -  Jun 9, 2019   
    It is evident there are a variety of NMDA receptor antagonist agents that should be considered for treatment of neuropathic pain. Nevertheless, continued and further investigation of the 8 pharmacologic agents is needed to continue to evaluate their efficacy for treatment of neuropathic pain.
  • ||||||||||  memantine / generics
    Biomarker, Journal:  Current and Future Treatments in Alzheimer's Disease. (Pubmed Central) -  Jun 7, 2019   
    ...Food and Drug Administration (FDA) approved AD medications, cholinesterase-inhibitors (ChEIs), and the N-methyl-d-aspartate (NMDA) antagonist memantine, when utilized as part of a comprehensive care plan, while generally considered symptomatic medications, can provide modest "disease course-modifying" effects by enhancing cognition, and reducing loss of independence...Intensive research efforts are underway to develop more accurate and practical AD diagnostic biomarkers and clinical tools and better therapeutics. Ongoing research studies for primary and secondary prevention of AD and clinical trials evaluating symptomatic and disease-modifying treatments in symptomatic AD are directed at diverse therapeutic targets including neurochemicals, amyloid and tau pathological processes, mitochondria, inflammatory pathways, neuroglia, and multimodal lifestyle interventions.
  • ||||||||||  memantine / Generic mfg.
    Biomarker, Trial completion:  Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia (clinicaltrials.gov) -  Jun 7, 2019   
    P1/2,  N=60, Completed, 
    Even though ACA reversed this suppression, no improvement in spatial memory was observed following ACA treatment. Recruiting --> Completed
  • ||||||||||  memantine / generics
    Journal:  Crystal structure of memantine-carb-oxy-borane. (Pubmed Central) -  May 23, 2019   
    A scattering contribution of 255 electrons was removed. The crystal studied was refined as a two-component twin.
  • ||||||||||  memantine / generics
    Journal:  Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. (Pubmed Central) -  May 22, 2019   
    Thus, the focus of this review is primarily to discuss the efficacy of MEM in preclinical models of AD, consider possible combinations of this drug with others, and then evaluate possible reasons for its lack of efficacy in clinical trials. Finally, applications in other pathologies are also considered.
  • ||||||||||  memantine / Generic mfg., rivastigmine / Generic mfg.
    New trial:  Deep Brain Stimulation for Alzheimer's Disease (clinicaltrials.gov) -  May 22, 2019   
    P=N/A,  N=30, Recruiting,